Basque researchers have turned to a drug that can reduce mortality from pneumonia caused by COVID-19 disease. The dose of glucocorticoid methylprednisolone can reduce patient mortality and prevent intubation. It is the result of a study carried out by the Hospital de Cruces, Biocruces Bizkaia, the University of the Basque Country and the biomedical research center CIBERESP.
As reported by EiTB, the study has been published by the scientific journal Plos One and is available on the Internet. According to the specifications, after three days of collection of high doses of methylprednisolone, patients have evolved positively.
This hormone, which helps regulate carbohydrate metabolism, helps to reduce the risk of mortality and prevent intubation. Thus, fewer cases of severe diseases would be admitted to the ICU.
Horren arabera, datorren astelehenetik aurrera, orain arte COVID-19ari aurre egiteko neurriak bertan behera geratuko dira Eusko Jaurlaritzaren eskumeneko alorretan. Labi bera ere desegin egingo dute.
That's the summer that we have, and with it the holidays that we usually link to this season, as if they were a reward to everything that has been given throughout the year. And again people want to go away. He wants to be on the famous coast, marvelous nature or the world's... [+]